Karyopharm Therapeutics (KPTI) Shares Outstanding (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Shares Outstanding (Entity) came in at $10935.0 in Q4 2025, up 34.58% YoY from $8125.0 in Q4 2024, and up 26.14% on a QoQ basis from $8669.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Shares Outstanding (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Shares Outstanding (Entity) data on file, last reported at $10935.0 in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 34.58% year-over-year to $10935.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10935.0 (up 34.58% YoY) and the FY2025 annual result came in at $10935.0, up 34.58% from the prior year.
- Shares Outstanding (Entity) advanced to $10935.0 in Q4 2025, from $8669.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $8.3 million in Q2 2024 to a low of $4968.0 in Q1 2021.
- A 5-year average of $4.2 million and a median of $5.2 million in 2021 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 106479.41% — and 2025, when it tumbled 99.9%.
- Tracing KPTI's Shares Outstanding (Entity) over 5 years: stood at $5.0 million in 2021, then grew by 8.09% to $5.5 million in 2022, then surged by 40.36% to $7.7 million in 2023, then plunged by 99.89% to $8125.0 in 2024, then surged by 34.58% to $10935.0 in 2025.
- The last three Shares Outstanding (Entity) figures came in at $10935.0 (Q4 2025), $8669.0 (Q3 2025), and $8620.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 28.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.94 Mn |
| Dec 31, 2025 | 10,935.00 |
| Sep 30, 2025 | 8,669.00 |
| Jun 30, 2025 | 8,620.00 |
| Mar 31, 2025 | 8,470.00 |
| Dec 31, 2024 | 8,125.00 |
| Sep 30, 2024 | 8,334.00 |
| Jun 30, 2024 | 8.07 Mn |
| Mar 31, 2024 | 7.70 Mn |
| Dec 31, 2023 | 7.62 Mn |
| Sep 30, 2023 | 7.63 Mn |
| Jun 30, 2023 | 7.61 Mn |
| Mar 31, 2023 | 7.57 Mn |
| Dec 31, 2022 | 5.46 Mn |
| Sep 30, 2022 | 5.35 Mn |
| Jun 30, 2022 | 5.31 Mn |
| Mar 31, 2022 | 5.17 Mn |
| Dec 31, 2021 | 5.01 Mn |
| Sep 30, 2021 | 5.03 Mn |
| Jun 30, 2021 | 5.01 Mn |